Department of Immunology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Division of Vaccine Discovery, La Jolla Institute of Allergy and Immunology, La Jolla, California, USA.
JCI Insight. 2019 Mar 14;5(8):127882. doi: 10.1172/jci.insight.127882.
MHC I-restricted epitopes of chicken ovalbumin (OVA) were originally identified using CD8 T cells as probes. Here, using bioinformatics tools, we identify four additional epitopes in OVA in addition to a cryptic epitope. Each new epitope is presented in vivo, as deduced from the lack of CD8 response to it in OVA-transgenic mice. In addition, CD8 responses to the known and novel epitopes are examined in C57BL/6 mice exposed to the OVA-expressing tumor E.G7 in several ways. No responses to any epitope including SIINFEKL are detected in mice with growing E.G7 or mice immunized with the tumor. Only in E.G7-bearing mice treated with an anti-CTLA4 antibody which depletes tumor-infiltrating regulatory T cells, CD8 responses to SIINFEKL and the novel epitope EKYNLTSVL are detected. Finally, all epitopes fails to treat mice with pre-existing tumors. These observations force an important re-consideration of the common assumptions about the therapeutic value of neoepitopes detected by CD8 responses in tumor-bearing hosts.
鸡卵清白蛋白(OVA)的 MHC I 限制性表位最初是使用 CD8 T 细胞作为探针鉴定的。在这里,我们使用生物信息学工具,除了一个隐匿表位外,还在 OVA 中鉴定了另外四个新的表位。每个新表位都在体内呈现,这是从 OVA 转基因小鼠对其缺乏 CD8 反应中推断出来的。此外,通过多种方式检查了暴露于表达 OVA 的肿瘤 E.G7 的 C57BL/6 小鼠中对已知和新表位的 CD8 反应。在生长中的 E.G7 或用肿瘤免疫的小鼠中,未检测到针对任何表位(包括 SIINFEKL)的反应。只有在接受抗 CTLA4 抗体治疗的荷瘤小鼠中,才会检测到针对 SIINFEKL 和新表位 EKYNLTSVL 的 CD8 反应。最后,所有表位都未能治疗患有预先存在肿瘤的小鼠。这些观察结果迫使人们对肿瘤宿主中 CD8 反应检测到的新表位的治疗价值的常见假设进行重要的重新考虑。